Director / Principle Scientist ARD Veranova Acton, Massachusetts
Edaravone, a free-radical scavenger used in the treatment of acute ischemic stroke and amyotrophic lateral sclerosis, is susceptible to oxidative degradation. This study evaluated the stability of Edaravone under acidic, alkaline, oxidative, thermal, humidity, and photolytic stress conditions in accordance with ICH guidelines. HPLC analysis showed that Edaravone was stable under acidic, alkaline, thermal, humidity, and photolytic conditions, while significant degradation was observed under oxidative stress. Three degradation impurities were detected, comprising one major impurity (~13.8%) and two minor impurities (~0.8% and ~0.2%). The major impurity and one minor impurity were isolated using preparative chromatography and characterized by LC–MS and NMR spectroscopy. The third minor impurity could not be isolated due to its low abundance, and its structure was tentatively proposed based on mass spectrometric data. A plausible oxidative degradation pathway was proposed. This study enhances understanding of Edaravone stability and supports formulation development and drug safety.
Learning Objectives:
Upon completion, participant will be able to know about the Novel Degradants of Edaravone.
Evaluate the stability profile of Edaravone under ICH-recommended stress conditions, including acidic, alkaline, oxidative, thermal, humidity, and photolytic environments.
Identify and quantify oxidative degradation impurities formed in Edaravone using HPLC, with emphasis on the major and minor degradation products.
Isolate and structurally characterize degradation products through preparative chromatography, LC-MS, and NMR spectroscopy to determine their chemical identities. Propose a plausible oxidative degradation pathway for Edaravone by integrating chromatographic and spectrometric data.
